The EMJ Podcast: Insights For Healthcare Professionals

In the final episode of this series, Professor Habib Naqvi MBE looks ahead to the future of equitable healthcare. From the economic impact of health inequalities and rebuilding trust with underserved communities to the role of patients in shaping healthcare policy, he explores the changes needed to create a fairer NHS. The episode also examines emerging challenges in health equity, lessons from international approaches, and the reasons for optimism about the future of race equity and healthcare. Timestamps: ·       1:07 – Equity: A Moral and Economic Priority ·       04:06 – The Bigger Picture ·       05:28 – Building Trust ·       07:50 – International Partnerships ·       10:00 – New Trends ·       11:48 – Patients and Communities ·       14:30 – Intersectionality ·       15:59 – Looking Forward ·       17:46 - Optimism

What roles do leadership, workforce equality, and accountability play in achieving health equity? In Part 2, Professor Habib Naqvi MBE explores the link between staff experience and patient outcomes, discusses the realities faced by ethnic minority NHS staff, examines why translating good intentions into meaningful action remains challenging, and explains how data, leadership, and openly addressing racism are essential to driving lasting change across the healthcare system. Timestamps ·       01:01– Workforce Inequality ·       05:37 – From Policy to Action ·       07:29 – Data Limitations ·       09:53 – The 'Model Organisation' ·       12:34 – Accountability

In this episode of Hema Now, Lucas Kühne explores the evolving landscape of immune thrombotic thrombocytopenic purpura, discussing advances in treatment, the importance of early recognition and accurate diagnosis, the growing role of real-world evidence, and why international collaboration is critical to accelerating research and improving patient care in rare thrombotic microangiopathies. Timestamps:   00:00 – Introduction  01:40 - Career inspiration and TMA interest   03:11 - Major advances in iTTP treatment   05:05 - Recognising iTTP earlier   07:08 - Distinguishing between TMAs   09:05 - Value of real-world evidence   12:13 - Future priorities in iTTP research   13:32 - Importance of research collaboration   14:57 - Advice for future researchers   15:53 - Future of TMA care 

In this episode, Habib Naqvi explores the current state of race and health inequalities in the UK. Marking the fifth anniversary of the NHS Race and Health Observatory, he reflects on how the conversation around health equity has evolved, discusses the persistent disparities affecting ethnic minority communities, examines the role of healthcare systems and wider social determinants, and addresses the misconceptions that continue to hinder progress towards equitable healthcare.

 In this rapid-fire episode, Habib Naqvi answers key questions on health equity, race and the future of the NHS. From the most overlooked determinants of health and common misconceptions about health inequalities to leadership, the achievements of the NHS Race and Health Observatory, and the changes needed to create a fairer healthcare system, this episode offers concise insights for anyone interested in improving health outcomes and advancing equity.

This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits. The speakers were compensated by Sanofi and Regeneron in connection with this program.   COPD trial outcomes are not all equal, yet conventional endpoints can make it difficult to weigh severe events, exacerbations, lung function, and symptom burden within a single clinical picture.   In this AMJ podcast, Sanjay Ramakrishnan and Simon Couillard discuss how win ratio methodology may help capture a broader, more clinically meaningful view of treatment benefit by comparing outcomes across a prespecified hierarchy.   Listen to the full episode to learn:   Why standard COPD endpoints may not tell the full story How win ratio analysis prioritizes outcomes by clinical importance What the pooled BOREAS and NOTUS analysis showed How this approach could shape future respiratory trial design Speakers: Sanjay Ramakrishnan, Clinical Senior Lecturer, UWA Medical School, Centre for Respiratory Health, The University of Western Australia, Perth, Australia Simon Couillard, Professor, Faculty of Medicine and Health, Université de Sherbrooke, Quebec, Canada

In the final episode, Veeru Kasivisvanathan discusses the future of prostate cancer diagnosis, including AI-assisted MRI interpretation, genomic risk prediction, polygenic risk scores, and the opportunities and challenges of population screening. Discover how precision technologies could reshape prostate cancer care over the next decade. Timestamps: 00:57 – AI and MRI 02:25 – PARADIGM study 02:51 – Large-scale MRI screening 04:56 – Genomics and polygenic risk scores 06:45 – Future optimism of prostate cancer

Veeru Kasivisvanathan joins host Catherine Glass to discuss how MRI-first pathways have transformed prostate cancer diagnosis. Discover how the landmark PRECISION trial reshaped clinical practice, why targeted biopsy improves diagnostic accuracy, and how clinicians are balancing precision with access as MRI becomes the new standard. Timestamps: 01:05 – Traditional diagnostic approaches 02:55 – PRECISION trial 05:03 – MRI challenges

Veeru Kasivisvanathan joins host Catherine Glass to discuss how MRI-first pathways have transformed prostate cancer diagnosis. Discover how the landmark PRECISION trial reshaped clinical practice, why targeted biopsy improves diagnostic accuracy, and how clinicians are balancing precision with access as MRI becomes the new standard. 01:05 – Traditional diagnostic approaches 02:55 – PRECISION trial 05:03 – MRI challenges

In this rapid-fire episode, Veeru Kasivisvanathan answers key questions on prostate cancer diagnosis, MRI, prostate biopsy, overdiagnosis, AI, and future innovations. From common misconceptions to emerging technologies, this concise episode delivers expert insights into one of the fastest-evolving areas of urology.

 In this episode, Anna Caldwell speaks with paediatric allergist and immunologist Zachary Rubin about the rise of medical misinformation, vaccine hesitancy, and the opportunities and challenges of social media in healthcare. They discuss common allergy myths, how clinicians can effectively communicate evidence-based medicine online, and what patients can do to prepare for the 2026 allergy season.

In this episode of Hema Now, Megan Melody speaks about the evolution of CAR-T cell therapy and its impact on lymphoma care. She explores the major advances that have transformed outcomes for patients with relapsed and refractory disease, the unanswered questions shaping current research, and the practical challenges of building successful cellular therapy programmes. The conversation also covers equitable access to treatment, the role of quality standards and accreditation, personalised approaches to CAR-T therapy, and the importance of physician leadership and mentorship in shaping the future of academic haematology. Timestamps:   00:00 – Introduction   01:13 – Journey into Haematology and Lymphoma   04:19 – Major Advances in CAR-T   06:00 – Unanswered Questions After CAR-T   07:45 – Building Successful Cellular Therapy Programmes   09:06 – Improving Access to CAR-T   12:55 – Evolving Standards in Cellular Therapy   14:16 – Towards Personalised CAR-T Treatment   16:00 – Physician Leadership in Academic Medicine   17:10 – Career Advice for Future Specialists   19:02 – Future Directions in Cellular Therapy 

What does the future hold for kidney stone management? In Part 3, David S. Goldfarb explores disparities in care, promising areas of research, and the move towards more personalised approaches to prevention and treatment. He also discusses the impact of climate change on kidney stone risk and shares why he remains optimistic about the future of kidney stone care. Timestamps: 00:46 – Global warming 02:23 – Emerging research/treatments 03:57 – Asymptomatic kidney stones 04:58 – Broad, empiric approach to treatment 08:29 – Occupation as a risk factor for kidney stones 09:56 – Multidisciplinary care 11:51 – Climate change 13:47 – Calcium and kidney stones

What are the most effective ways to prevent kidney stones from recurring? In Part 2, David S. Goldfarb discusses evidence-based prevention strategies, including dietary counselling, hydration, and the role of pharmacological therapies.

In this episode of Onc Now, Vernon Sondak reflects on the remarkable evolution of melanoma care over the course of his career. He discusses how breakthroughs in surgery, immunotherapy, targeted therapies, and neoadjuvant treatment have transformed outcomes for patients with melanoma and influenced treatment strategies across oncology. The conversation also explores the challenges of paediatric melanoma, the importance of multidisciplinary collaboration, and the future priorities for melanoma research and patient care.  Timestamps:   00:00 – Introduction   01:30 - Melanoma Care Through the Years   06:52 - Sentinel Node Biopsy Impact Today   12:28 - Paediatric Melanoma Care Challenges   21:45 - Collaboration Driving Melanoma Progress   24:57 - Translating Research into Patient Care   31:30 - Exciting Advances in Systemic and Neoadjuvant Therapy   39:06 - Three Wishes for Melanoma Care 

What causes kidney stones to form, and why are they becoming increasingly common? In Part 1, David S. Goldfarb explores the physiological mechanisms behind kidney stone disease, the evolving roles of diet, metabolism, and hydration, and the links between kidney stones and broader metabolic conditions, including metabolic syndrome and fatty liver disease. He also reflects on how advances in research have transformed our understanding of risk factors, genetics, and disease prevention.

In this quickfire episode, David S. Goldfarb answers key questions about kidney stone disease, from common misconceptions and risk factors to the roles of genetics, lifestyle, hydration, and prevention. He also discusses changing prevalence trends, and the steps clinicians and patients can take to reduce the burden of this increasingly common condition.

In the final episode, Salvatore Brugaletta explores the future of percutaneous coronary intervention, including AI-assisted decision-making, personalised device selection, and next-generation coronary therapies. Discover how innovation could further improve outcomes for patients with coronary artery disease.  Timestamps:  0:50 – 10 years from now  2:17 – AI  3:47 – Personalised medicine  5:34 – Breakthroughs   7:02 – Salvatore's vision

In Part 2, Salvatore Brugaletta discusses the rise, challenges, and future potential of bioresorbable vascular scaffolds. Learn how advances in material science are improving device performance, which patients may benefit most, and what emerging technologies could redefine coronary intervention.  Timestamps:  0:52 – Bioresorbable scaffold enthusiasm  3:16 – Which patients will benefit?  4:40 – Material Science Advancements  5:48 – Device Innovations  7:02 – Translational Hurdles 

In this episode of Hema Now, Jorge Cortes reflects on the remarkable evolution of leukaemia treatment throughout his career, from the transformation of chronic myeloid leukaemia outcomes through targeted therapies to the rapidly changing landscape of acute myeloid leukaemia. He discusses the growing importance of biomarkers and patient-reported outcomes, the value of international collaboration, and how precision medicine is reshaping clinical research. Looking ahead, Cortes shares the developments in immunotherapy and personalised care that he believes could define the next era of leukaemia treatment. Timestamps:   00:00 – Introduction   01:01 – Inspiration for Haematology and Leukaemia  02:40 – Transforming Chronic Myeloid Leukaemia Care  04:55 – Future Challenges in CML  07:21 – Evolution of AML Treatment  09:50 – Biomarkers and Personalised Leukaemia Care  11:45 – Balancing Outcomes and Quality of Life  14:02 – International Collaboration in CML  16:33 – The Future of Clinical Research  20:03 – Building a Haematology Academic Career  22:04 – Exciting Advances in Leukaemia Research

Salvatore Brugaletta joins host Catherine Glass to explore how intracoronary imaging has transformed modern percutaneous coronary intervention (PCI). From intravascular ultrasound and optical CT to stent optimisation, vascular dysfunction, and AI-enhanced image interpretation, this episode examines the technologies improving procedural precision and patient outcomes.  Timestamps:  0:55 – IVUS and OCT  2:58 – Endothelial recovery  4:55 – Stent failure mechanisms  6:19 – Barriers to adoption  8:18 – Innovations in imaging 

In this rapid-fire episode, Salvatore Brugaletta answers key questions on interventional cardiology, coronary imaging, bioresorbable scaffolds, vascular healing, and the future of percutaneous coronary intervention. From AI-assisted procedures to device innovation and career advice, this concise episode offers expert insight into the evolving world of coronary intervention.   

In this episode of Onc Now, Mary Disis, Director of the University of Washington's Medicine Cancer Vaccine Institute, Seattle, USA, explores the science and future of cancer vaccines. She discusses how vaccines fit into today's immunotherapy landscape, the evolution of human epidermal growth factor receptor 2 (HER2)-targeted therapies, progress in breast cancer vaccines, the promise of cancer prevention, and the key priorities for survivorship and future oncology care.  Timestamps:   00:00 – Introduction   01:28 – Cancer Vaccines Explained   03:57 – Journey Into Cancer Immunology   06:38 – Cancer Vaccines in Immunotherapy   10:02 – Leading the Cancer Vaccine Institute   13:26 – Progress in Breast Cancer Vaccines   18:39 – HER2 Research and Treatment Evolution   21:30 – Future of Preventive Cancer Vaccines   26:39 – Priorities for Cancer Survivorship   30:30 – Three Wishes for Oncology's Future 

How does scientific evidence become public policy? In the final episode, Christopher Cogle discusses the challenges of translating healthcare innovation into large-scale policy change. Topics include housing policy and mortality, youth tobacco use, vaping regulation, and how the COVID-19 pandemic reshaped public health decision-making.  Timestamps:  00:49 – Public Startup  07:08 - Challenges  15:01 – Housing policy  16:28 – Tobacco policy  19:05 – COVID-19

In Part 2, Christopher Cogle examines the long-term realities facing cancer survivors. From vaccine hesitancy and quality-of-life disparities to healthcare access and survivorship policy, this episode explores how systems can better support patients beyond active treatment.  Timestamps:  00:50 – Vaccine hesitancy  04:33 – QoL after cancer  07:30 – Policy support   11:10 – Survivorship care 

In this episode of Hema Now, John Maher reflects on more than 2 decades at the forefront of CAR-T cell research. He discusses the major milestones that have transformed CAR-T therapy into a clinical reality, the biological barriers that continue to limit success in solid tumours, and the next-generation engineering approaches being developed to enhance efficacy and safety. Maher also shares insights into the origins of the CAR Mechanics Group, the challenge of overcoming the tumour microenvironment, and his vision for the future of cellular immunotherapy. Timestamps:   00:00 – Introduction   01:07 – Career Journey into Immunotherapy   02:22 – Key CAR-T Therapy Milestones   05:50 – Overcoming Solid Tumour Barriers   09:14 – Origins of CAR Mechanics   12:35 – Most Exciting Current Innovations   16:08 – Improving CAR-T Safety Profiles   20:07 – Challenges of Tumour Microenvironments   23:04 – Future of Cellular Immunotherapy   27:15 – Three Magic Wishes 

In this first deep dive, Christopher Cogle explores the evolving landscape of acute myeloid leukaemia (AML). He discusses the challenge of translating research into real-world outcomes, emerging immunotherapies, precision diagnostics, and how innovations such as the Acute Leukemia Methylome Atlas may reshape AML management in the future.  Timestamps:  00:55 – Research Gaps  03:50 – Biologics  05:46 – AML Atlas  09:15 – Immunotherapy 

Christopher Cogle joins the EMJ Podcast for a quickfire discussion on oncology, innovation, and public health policy. From personalised cancer care and AI in medicine to AML challenges and healthcare reform, he shares concise insights from across clinical medicine and policy leadership.

In the final episode, Sharonne N. Hayes discusses how structural inequities and unconscious bias continue to affect cardiovascular outcomes for women and minority patients. From improving diversity in research to leveraging social media responsibly, this episode explores what the future of equitable cardiovascular care could look like. Timestamps: 0:58 – Health equity 4:02 – Improving representation 7:10 – Role of social media 9:54 – 10-year prediction 11:08 – Sharonne's wish

In Part 2, Sharonne N. Hayes explores spontaneous coronary artery dissection (SCAD) and how it challenges traditional assumptions about heart attacks. Learn how SCAD differs from atherosclerotic disease, what recent research has uncovered, and how clinicians can navigate complex management decisions. Timestamps: 1:06 – What is SCAD? 2:47 – Practice-changing insights 6:35 – Hormonal influences 8:20 – Therapeutic ambiguity

 In this episode of Onc Now, Stephen Chan, Clinical Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong, explores the evolving landscape of hepatobiliary and pancreatic cancers. From advances in translational science and precision therapies to the challenges of neuroendocrine tumour care, Chan reflects on the progress made in oncology and the breakthroughs still needed. He also discusses his work with the Hand-in-Hand Cancer Foundation, highlighting the importance of education, compassion, and holistic support for patients and their families.  Timestamps:    00:00 – Introduction    01:18 - Current Hepatobiliary and Pancreatic Landscape   03:23 - Translational Science and Patient Outcomes   05:06 - Founding the Hand-in-Hand Cancer Foundation   06:53 - Advances in Precision Cancer Therapies   08:54 – Rising Incidence of Pancreatic Cancer Post COVID-19  10:45 - President of the International Liver Cancer Association  12:46 - Challenges in Neuroendocrine Tumour Care   14:32 - Future Breakthroughs in Cancer Care   16:02 - Three Wishes for Oncology's Future 

This podcast was developed by AMJ in collaboration with GSK and is sponsored by GSK. This information is scientific and non-promotional in nature, and intended for US audiences.   Less than 20% of biologic-eligible patients with GINA Step 5 asthma receive biologic therapy.1,2 In this AMJ podcast, experts discuss how real-world gaps in initiation, access, and adherence can affect whether patients start, stay on, and sustain benefit from biologic therapy over time.   Listen to the full episode to explore: Key real-world data on biologic initiation and adherence in severe asthma Patient cases showing common barriers across the care pathway Practical ways to uncover the burden of severe asthma The Start, Stay, Sustain framework for patient-centered care   Speakers: Justin Kwiatek, US Medical Affairs Lead, Respiratory Biologics, GSK Tom Corbridge, US Senior Medical Director, Respiratory Biologics, GSK   References Park J et al. Biologic underutilization and healthcare burden in US patients with Type 2 severe asthma. J Asthma Allergy. 2026;19:580937. Maselli DJ et al. Patient characteristics and social determinants of health influence adherence to biologic therapy for asthma. SEAAIS 80th Annual Meeting, October 23-26, 2025.

Sharonne N. Hayes joins host Saranya Ravindran to discuss how cardiovascular disease presents differently in women. From pregnancy-related complications and menopause to microvascular disease and gaps in clinician education, this episode explores the importance of sex-specific cardiovascular care. Timestamps: 1:04 – Sex-specific differences 2:43 – Pregnancy and preeclampsia 4:38 – Historic underdiagnosis 7:00 – Menopause and hormones 10:04 – Education and training 

In this rapid-fire episode, Sharonne N. Hayes answers key questions on women's cardiovascular health, SCAD, unconscious bias, prevention, and the future of equitable heart care. A concise, expert-led overview of the field.

In the final episode, Bryan Tucker explores the future of kidney stone prevention and treatment. From genetics and microbiome research to wearable hydration technology and AI-driven risk prediction, this episode examines how personalised medicine could transform nephrolithiasis care over the next decade. Timestamps: 01:01 – Future changes in kidney stone care 04:21 – Microbiome and stone risk 05:34 – AI-driven risk prediction 07:02 – Ideal future of care

In Part 2, Bryan Tucker discusses the balance between acute intervention and long-term prevention in kidney stone care. Learn why many patients never receive comprehensive metabolic evaluation, how healthcare systems prioritise procedures over prevention, and what changes are needed to improve recurrence prevention. Timestamps: 01:05 – Intervention and long-term prevention 04:01 – Gaps in follow-up evaluations 06:57 – Care changes for better prevention

This podcast has been funded by an educational grant from Viatris. Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease shaped by dysregulated immune pathways, variable organ involvement, and substantial patient burden. In this educational podcast, Anca Askanase explores how a deeper understanding of SLE immunology can help rheumatologists contextualize disease activity, evolving research, and guideline-based care. Topics covered: Key immune pathways involved in SLE pathophysiology, including innate and adaptive immune dysregulation  How pathway biology may help explain clinical heterogeneity and differences in disease activity between patients  What rheumatologists should consider when interpreting emerging pathway-based research and cross-disease immunology concepts  How current guideline-based care frames treatment goals, patient burden, and the evolving focus on remission in SLE  Speakers Anca D. Askanase, Chair, Department of Medicine, and Chief, Division of Rheumatology, Hospital for Special Surgery, New York, USA

In this episode of Hema Now, we speak with Cecilia Karlström about advances in rare and complex haematological disorders. She discusses the evolving understanding of platelet refractoriness and transfusion support, the challenges in diagnosing systemic mastocytosis, and how targeted therapies are reshaping outcomes in rare blood diseases. The conversation also explores the growing role of precision medicine, multidisciplinary care, and future priorities in haematology research.  Timestamps:     00:00 – Introduction     01:21 – Career inspiration in haematology origins   02:43 – Evolution of platelet refractoriness management   03:39 – Current state systemic mastocytosis care   05:03 – Diagnosing systemic mastocytosis challenges today   07;26 – Impact of targeted therapies mastocytosis   07:26 – Future precision medicine opportunities haematology   09:00 – Multidisciplinary care improving patient outcomes   10:25 – Improving equity rare disease access   11:43 – Exciting research areas haematological disorders   13:14 – Three wishes future haematology advances

Bryan Tucker joins host Catherine Glass to explore why kidney stone disease is becoming increasingly common worldwide. From dietary and metabolic drivers to male predominance and prevention strategies, this episode examines how nephrolithiasis reflects broader shifts in metabolic health and lifestyle. Timestamps: 01:13 – Increased prevalence 03:19 – Metabolic issues 04:30 – Increased prevalence in men 06:50 – Population-level prevention strategies 08:24 – Cardiometabolic syndrome

In this rapid-fire episode, Bryan Tucker answers key questions about kidney stone disease, from common myths and overlooked risk factors to hydration, prevention, and emerging technologies. Perfect for listeners short on time but looking for expert insights into the future of nephrolithiasis care.

In the final episode, Naveed Sattar explores the future of cardiometabolic medicine, from novel therapies and AI-driven risk prediction to integrated care pathways and the next generation of preventative strategies for diabetes and cardiovascular disease.  Timestamps:  0:56 – Novel interventions  2:10 – Digital health and AI  4:17 – Integrated care  5:26 – Future directions  7:11 – Naveed's prediction 

In Part 2, Naveed Sattar discusses obesity, ectopic fat, and cardiovascular risk. Learn how imaging and biomarkers are improving risk identification, why metabolic dysfunction matters beyond BMI, and how GLP-1 therapies are reshaping obesity and cardiovascular care.  Timestamps:  0:56 – Ectopic fat  11:44 – Metabolic dysfunction  13:42 – GLP-1 receptor agonists  19:05 – Mechanistic insights  21:31 – Societal issues 

Naveed Sattar joins host Catherine Glass to explore the complex relationship between diabetes and cardiovascular disease. From hyperglycaemia and inflammation to diabetes onset age and risk prediction, this episode examines the mechanisms and evidence shaping cardiometabolic care today.  Timestamps:  0:55 – Diabetes to heart disease  4:35 – Age of onset  6:21 – Statins  09:01 – Epidemiological insights  12:29 – Improving risk prediction 

In this rapid-fire episode, Naveed Sattar answers key questions on diabetes, cardiovascular disease, obesity, prevention, and emerging therapies. From precision medicine and GLP-1 receptor agonists to lifestyle interventions and research advice, this concise episode provides expert insight into the future of cardiometabolic medicine. 

In the final episode, the focus turns to prevention. Rachel Buckley examines whether Alzheimer's strategies should be sex-specific, the timing of interventions, and how lifestyle factors like physical activity contribute to brain resilience. The discussion also highlights gaps in research and the need for better integration of women's health data. Timestamps: 00:00:45:13 – Sex-disaggregated data for prevention 00:03:26:15 – Sex-specific timing for therapeutics 00:05:07:20 – Non-pharmacological interventions 00:07:58:02 – Gaps in reproductive data

This episode explores how reproductive ageing and biological sex influence Alzheimer's disease risk. Rachel Buckley discusses menopause, hormonal changes, genetic factors such as the X chromosome, and emerging evidence showing differences in tau accumulation between women and men. Timestamps: 00:00:55:03 – Menopause and Alzheimer's disease 00:04:51:11 – X chromosome in Alzheimer's disease 00:08:29:01 – Tau accumulation in women 00:10:43:09 – Hormone replacement therapy 00:14:22:24 – The sweet spot with hormone therapy

In this episode of Onc Now, Paolo Bironzo joins us to discuss the evolving landscape of thoracic oncology and the innovations transforming lung cancer care. From targeted therapies and immunotherapy selection to advances in mesothelioma treatment and molecular profiling, Bironzo shares insights into the challenges clinicians face today and the future of precision medicine. He also reflects on the importance of treatment de-escalation, the complexities of clinical trials, and offers advice for the next generation of oncologists. Timestamps:   00:00 – Introduction   00:51 – Inspiration Behind Thoracic Oncology   03:17 – Current Challenges in Lung Cancer   04:50 – Impact of Targeted Therapies   07:14 – Selecting Patients for Immunotherapy   08:04 – Advances in Mesothelioma Treatment   14:52 – Molecular Profiling in Thoracic Cancer   19:52 – Challenges in Lung Cancer Trials   22:05 – Predicting Immunotherapy Response Challenges   24:23 – Future of Precision Medicine   26:05 – Advice for Early-Career Oncologists   28:40 – Three Wishes for Cancer Therapy 

In this first deep dive, Rachel Buckley joins host Catherine Glass to explore how Alzheimer's disease risk can be detected before symptoms appear. From blood-based biomarkers like p-tau217, to AI-driven models of cognitive resilience, the episode examines how risk, progression, and protection can be better understood and predicted over time. Timestamps: 00:00:57:11 – Phosphorylated tau and amyloid-PET 00:08:15:05 – Biomarkers, risk, and progression 00:11:18:04 – Brain resistance and cognitive resilience 00:15:23:23 – AI biases

In this rapid-fire episode, Rachel Buckley answers key questions on Alzheimer's disease, covering sex differences in risk, early predictors of progression, brain resilience, and the most actionable prevention strategies. A concise overview of the evolving science behind personalised Alzheimer's care.

In the final episode, host Saranya and Helen Brough examine the key gaps in allergy care across prevention, diagnosis, and long-term management, and how these challenges impact families in practice. It explores barriers to early peanut introduction, highlights inequalities in allergy care and the populations most affected, and looks at how digital tools, education, and outreach could help improve access to evidence-based care.  Timestamps:  00:43 – Gaps in allergy care  04:07 –  Early peanut introduction  06:39 - Disparities in diagnosis  08:12 – Improve access to care 

In Part 2, we explore the role of the skin barrier in food allergy development, from how environmental allergen exposure can drive sensitisation to whether early skincare can help prevent disease. Drawing on studies such as SEAL and recent European eczema guidelines, it also tackles common misconceptions and parental concerns, including topical steroid withdrawal and how best to provide reassurance.  Timestamps:  00:54:02 – Skin allergen exposure  03:50 – Optimising the skin barrier   06:46 – Proactive treatment of atopic eczema  08:17 – Applying treatments  11:41 – Topical steroid withdrawal